FDA-cleared profile

MRI Planner

Spectronic Medical AB · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: MRI Planner creates synthetic CT images for photon external-beam radiation planning from MRI and can generate healthy-structure contours for specified brain, head-and-neck, and pelvic workflows; it is not intended to contour tumors or clinical target volumes.

Clinical role
MRI-to-synthetic-CT conversion, contour support, and dose-planning support under qualified review.
Images and patients
Radiotherapy Planning Imaging · Brain
Key limitation
Keep in mind: MRI Planner is not intended to automatically contour tumors or tumor clinical target volumes. MRI Planner does not display or store DICOM images. The user is advised to use existing softwares for radiotherapy treatment planning to display and modify generated images and contours.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: MRI Planner creates synthetic CT images for photon external-beam radiation planning from MRI and can generate healthy-structure contours for specified brain, head-and-neck, and pelvic workflows; it is not intended to contour tumors or clinical target volumes.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Brain Input: Based on a DICOM MR image stack, the software generates synthetic CT images and generates contours of anatomical structures in the MR image stack.
  • Who uses it?Intended users: Trained radiation oncologists, dosimetrists and physicists.
  • What does the software produce?Output: The software generates synthetic CT images that can be used for attenuation calculations in radiotherapy treatment planning and generates contours of anatomical structures in the MR image stack, to be used as a starting point for the manual delineation work required in radiotherapy treatment planning.
  • What is its most important limitation?Key limitation: MRI Planner is not intended to automatically contour tumors or tumor clinical target volumes. MRI Planner does not display or store DICOM images. The user is advised to use existing softwares for radiotherapy treatment planning to display and modify generated images and contours.

Clinical takeaway. Clinical role: MRI Planner creates synthetic CT images for photon external-beam radiation planning from MRI and can generate healthy-structure contours for specified brain, head-and-neck, and pelvic workflows; it is not intended to contour tumors or clinical target volumes.

Evidence takeaway. Evidence from the reviewed source record: K211841 reports 244 MR/CT patients for synthetic CT development and 175 MR patients for prostate contours. Dose testing included 58 pelvic and 75 brain or head-and-neck patients, with average dose differences near zero and high-dose gamma averages of 99.8% to 99.9%; auto-contour Dice values were 0.95 for bladder, 0.90 for colon, and 0.96 for femoral heads in 51 patients.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
MRI Planner creates synthetic CT images for photon external-beam radiation planning from MRI and can generate healthy-structure contours for specified brain, head-and-neck, and pelvic workflows; it is not intended to contour tumors or clinical target volumes.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
MRI-to-synthetic-CT conversion, contour support, and dose-planning support under qualified review.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Based on a DICOM MR image stack, the software generates synthetic CT images and generates contours of anatomical structures in the MR image stack.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description supports a DICOM MR image-stack input; patient metadata and release-specific planning inputs are not stated.

Output and clinician action
The software generates synthetic CT images that can be used for attenuation calculations in radiotherapy treatment planning and generates contours of anatomical structures in the MR image stack, to be used as a starting point for the manual delineation work required in radiotherapy treatment planning.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description supports synthetic CT and contour outputs and describes contours as a starting point for manual delineation; it does not state approval or session-management wording.

Care setting
Radiation-oncology departments using MRI-only planning workflows and compatible treatment-planning systems.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Trained radiation oncologists, dosimetrists and physicists.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications name these trained users and do not name radiation therapists.

Limitations
MRI Planner is not intended to automatically contour tumors or tumor clinical target volumes. MRI Planner does not display or store DICOM images. The user is advised to use existing softwares for radiotherapy treatment planning to display and modify generated images and contours.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet provides the tumor/CTV and display/storage boundaries and the instruction to use existing radiotherapy-planning software; qualified final approval wording is not stated.

Evidence summary
K211841 reports 244 MR/CT patients for synthetic CT development and 175 MR patients for prostate contours. Dose testing included 58 pelvic and 75 brain or head-and-neck patients, with average dose differences near zero and high-dose gamma averages of 99.8% to 99.9%; auto-contour Dice values were 0.95 for bladder, 0.90 for colon, and 0.96 for femoral heads in 51 patients.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K211841 reports 244 MR/CT patients for synthetic CT development and 175 MR patients for prostate contours. Dose testing included 58 pelvic and 75 brain or head-and-neck patients, with average dose differences near zero and high-dose gamma averages of 99.8% to 99.9%; auto-contour Dice values were 0.95 for bladder, 0.90 for colon, and 0.96 for femoral heads in 51 patients.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Synthetic-CT training patients

244 patients

  • EndpointMR-to-synthetic-CT dataset
  • PopulationMRI Planner
  • Tested versionMRI Planner

Pelvic dose cases

58 patients

  • EndpointDose comparison
  • PopulationMRI Planner
  • Tested versionMRI Planner

Brain or head-and-neck dose cases

75 patients

  • EndpointDose comparison
  • PopulationMRI Planner
  • Tested versionMRI Planner

Mean pelvic dose difference

0.02 %

  • EndpointSynthetic CT versus CT dose comparison
  • PopulationMRI Planner
  • Tested versionMRI Planner

High-dose pelvic gamma average

99.9 %

  • EndpointSynthetic CT dose comparison
  • PopulationMRI Planner
  • Tested versionMRI Planner

Bladder contour Dice

0.95 coefficient

  • EndpointAuto-contour overlap
  • PopulationMRI Planner
  • Tested versionMRI Planner

Colon contour Dice

0.9 coefficient

  • EndpointAuto-contour overlap
  • PopulationMRI Planner
  • Tested versionMRI Planner

Femoral-head contour Dice

0.96 coefficient

  • EndpointAuto-contour overlap
  • PopulationMRI Planner
  • Tested versionMRI Planner

K211841 FDA performance package for MRI Planner

  • DesignManufacturer synthetic-CT, dose-comparison, and auto-contour validation
  • Population244 MR/CT patients for synthetic CT, 175 for prostate contours, 58 pelvic and 75 brain or head-and-neck dose cases, and 51 contour cases
  • Scopeexact submission
  • Tested versionMRI Planner
  • IndependenceSponsor or vendor study

K211841

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

3 unlinked candidate evidence records are retained for source review and excluded from this evidence display.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K211841 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Based on a DICOM MR image stack, the software generates synthetic CT images and generates contours of anatomical structures in the MR image stack.

    Scope: Exact FDA submission. The exact device description supports a DICOM MR image-stack input; patient metadata and release-specific planning inputs are not stated.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K211841: MRI Planner

  2. Routing

    Source context, not route validation: DICOM MRI, synthetic CT, RTSTRUCT, and planning-system exchange; validate registration, patient identity, geometry, density assignment, dose, and export.

    Scope: Product family. Current vendor materials are product-family evidence for K211841; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K211841: MRI Planner · Spectronic MRI Planner

  3. AI processing

    Source context, not route validation: Release-specific clinical software deployed on a workstation or server within the radiation-oncology network.

    Scope: Product family. Current vendor materials are product-family evidence for K211841; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K211841: MRI Planner · Spectronic MRI Planner

  4. Returned objects

    Source context, not route validation: The software generates synthetic CT images that can be used for attenuation calculations in radiotherapy treatment planning and generates contours of anatomical structures in the MR image stack, to be used as a starting point for the manual delineation work required in radiotherapy treatment planning.

    Scope: Exact FDA submission. The exact device description supports synthetic CT and contour outputs and describes contours as a starting point for manual delineation; it does not state approval or session-management wording.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K211841: MRI Planner

  5. Viewer/worklist/report

    Unresolved route: The software generates synthetic CT images that can be used for attenuation calculations in radiotherapy treatment planning and generates contours of anatomical structures in the MR image stack, to be used as a starting point for the manual delineation work required in radiotherapy treatment planning.

    Scope: Exact FDA submission. The exact device description supports synthetic CT and contour outputs and describes contours as a starting point for manual delineation; it does not state approval or session-management wording.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K211841: MRI Planner

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Release-specific clinical software deployed on a workstation or server within the radiation-oncology network.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K211841; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Integration
DICOM MRI, synthetic CT, RTSTRUCT, and planning-system exchange; validate registration, patient identity, geometry, density assignment, dose, and export.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K211841; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Training
Only qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Synthetic CT and auto-contours are limited to labeled anatomy and structures and are not tumor or clinical-target-volume delineation; qualified staff must verify images, contours, dose, and plans before treatment.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K211841; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K211841 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM MRI, synthetic CT, RTSTRUCT, and planning-system exchange; validate registration, patient identity, geometry, density assignment, dose, and export.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Synthetic CT and auto-contours are limited to labeled anatomy and structures and are not tumor or clinical-target-volume delineation; qualified staff must verify images, contours, dose, and plans before treatment.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Synthetic CT and auto-contours are limited to labeled anatomy and structures and are not tumor or clinical-target-volume delineation; qualified staff must verify images, contours, dose, and plans before treatment.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K211841
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications establish brain, head-neck, pelvis, and the prostate-patient bladder, colon, and femoral-head contour scope; the current brain-only anatomy is too narrow. Controlled directory display reconciled from exact FDA wording: MRI Planner is indicated for radiotherapy planning of adult patients for primary and metastatic cancers in the brain and head-neck regions, as well as soft tissue cancers in the pelvic region. MRI Planner generates synthetic CT images for radiation attenuation estimation purposes for the pelvis, brain and head-neck regions only. MRI Planner generates automatically derived contours of the bladder, colon and femoral heads, for prostate cancer patients only. -> Brain.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-08-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
14Source classes checked
6Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 6 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 6 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

13 sources - 3 history items

Source ledger

  1. FDA K211841: MRI Planner

    U.S. Food and Drug Administration - Published 2022-08-25 - Accessed 2026-09-19

    Scope: purpose, modality, evidenceSummary, anatomy, intendedUsers, input, output, limitations, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Spectronic MRI Planner

    Spectronic Medical - Accessed 2026-09-03

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  8. Head and neck cancer patient positioning using synthetic CT data in MRI-only radiation therapy.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  9. Evaluation of magnetic resonance imaging derived synthetic computed tomography for proton therapy planning in prostate cancer.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  10. Standardizing MRI-only radiotherapy commissioning: Benchmark dataset and acceptance levels from the MESCAL initiative.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  11. Feasibility of Magnetic Resonance-based Synthetic Computed Tomography for Proton Dose Calculation in Prostate Cancer.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  12. Clinical validation of a commercially available deep learning software for synthetic CT generation for brain.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  13. Clinical implementation of deep learning-based synthetic CT for MRI-only volumetric modulated arc therapy in head and neck and pelvic cancer patients.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

Research history

  1. K211841 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K193109

MRCAT brain

Philips Medical Systems MR Finland

Generation of MR-derived attenuation information for photon radiotherapy planning of primary and metastatic brain tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain
Decision
2020-01-24
FDA-cleared K252190

DeepBT Detector-Plus

Aitewan Biomedical Technology, Inc.

Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain tumors, including metastases, meningiomas, and acoustic neuromas
Decision
2026-04-10
FDA-cleared K252304

syngo.via RT Image Suite VC10

Varian Medical Systems, Inc.

Authorized purpose: syngo.via RT Image Suite VC10 provides three-dimensional and four-dimensional multimodality visualization, registration, fusion, contouring, and planning support for radiation-treatment preparation.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain, pelvis, thorax, abdomen, targets, organs at risk, and moving tumors or organs
Decision
2026-03-18
FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history